Clinical trial NCT06623461: LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
Official title: A Phase II Randomized Trial of LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Patients With Advanced Melanoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Melanoma
Lead sponsor: Canadian Cancer Trials Group
Sponsor class: NETWORK
Collaborators: name: Canadian Institutes of Health Research (CIHR)
name: Canadian Cancer Society (CCS)
name: Weston Family Foundation
First posted: 2024-10-02
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is being done to answer the following question: Can the chance of melanoma growing or spreading be lowered by receiving a treatment called LND101 for Fecal Microbiota Transplant (FMT) in addition to the usual immunotherapy treatment called Immune Checkpoint Blockade (ICB)? FMT treatment changes the bacteria in your gut called the microbiome.

Detailed description: We are doing this study because we want to find out if this approach (adding LND101 FMT to ICB) is better or worse than the usual approach (ICB only) for advanced melanoma. The usual approach is defined as care most people get for advanced melanoma.

The usual approach for patients who are not in a study is treatment with immunotherapy drugs called immune checkpoint blockade (ICB) drugs. Immunotherapy works by activating the immune system to target the cancer. This may help to slow down the growth of cancer and may cause cancer cells to die.

Eligibility criteria: Inclusion Criteria:

* Participants must have a confirmed histological diagnosis of cutaneous melanoma or melanoma of unknown primary.
* Participants must have stage IV or advanced unresectable disease.
* No prior ICB treatment for advanced unresectable or metastatic disease. Participants may have received adjuvant or neoadjuvant ICB if last dose was given ≥ 6 months prior to enrollment
* Prior targeted therapy with BRAF/MEK inhibition in the adjuvant or advanced / metastatic setting is permitted if at least 2 weeks have elapsed between the last dose and study enrollment. Participants must have recovered to ≤ grade 1 from all toxicity related to BRAF/MEK inhibition
* Prior radiation therapy is permitted if at least 7 days have elapsed between the last fraction and study enrollment. Participants must have recovered to ≤ grade 1 from all toxicity related to prior radiotherapy.
* Previous major surgery is permitted provided that surgery occurred ≥ 14 days prior to participant enrollment and that wound healing has occurred.
* Participants must have measurable disease as per RECIST 1.1/ iRECIST.
* Participants must be at least 18 years of age.
* Participants must have an ECOG performance status of 0, 1, or 2.
* The participant's standard-of-care ICB regimen must be selected prior to enrollment and must stay the same, regardless of arm assignment, post-enrollment
* Participants must demonstrate adequate organ function Participants must be able to ingest capsules.
* Participants must consent to provision of samples of blood and stool for correlative marker analysis.
* Participants must consent to provision of, and investigator must agree to submit, a representative archival formalin fixed paraffin block of tumour tissue for correlative analyses when tumour tissue is available.
* Participants must have access to provincially-funded standard-of-care ICB treatment.
* Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrollment in the trial to document their willingness to participate.
* Participants must be accessible for treatment and follow-up. Investigators must assure themselves the participants randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
* Protocol ICB treatment must begin within 14 calendar days after participant enrollment.
* Participants of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion Criteria:

* Participants with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
* Participants who have received antibiotics within 14 days of enrollment.
* Participants with systemic corticosteroid use \> 10mg per day.
* Participants with concurrent treatment with other anti-cancer therapy.
* Participants that have received live attenuated vaccination administered within 30 days prior to randomization. Note: Seasonal vaccines for influenza and COVID-19 are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and not allowed.
* For participants with history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
* Participants with absolute contraindications to FMT including: a) Toxic megacolon; b) Inflammatory bowel disease; c) Severe dietary allergies
* Participants with hypersensitivity to PegLyte®
* Participants with symptomatic brain metastases unless brain lesions are shown to be stable, according to the following definitions:

  1. without evidence of progression for at least four weeks prior to randomization and have no evidence of new or enlarging brain metastases; or
  2. treated with surgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases; or
  3. treated with stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.
* Participants with leptomeningeal disease.
* Participants with any uncontrolled autoimmune disease that requires active immunosuppressive agents.
* Participants who are solid organ transplantation recipients.
* Participants living with HIV.
* Participants with active infection. Participants may be eligible following recovery. Participants requiring antibiotics require 2-week washout period prior to enrollment.
* Participants that are pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial.

Primary outcomes:
measure: Progression-free Survival
timeFrame: 4 years
Secondary outcomes:
measure: Overall Survival
timeFrame: 4 years
measure: Objective Response Rate
timeFrame: 4 years
measure: Number and severity of adverse events assessed with CTCAE version 5.0
timeFrame: 4 years
Other outcomes:
Locations:
city: London
country: Canada
facility: London Health Sciences Centre Research Inc.
state: Ontario
city: Ottawa
country: Canada
facility: Ottawa Hospital Research Institute
state: Ontario
city: Montreal
country: Canada
facility: CHUM-Centre Hospitalier de l'Universite de Montreal
state: Quebec
city: Montreal
country: Canada
facility: The Jewish General Hospital
state: Quebec
city: Trois-Rivieres
country: Canada
facility: Centre hospitalier regional de Trois-Rivieres
state: Quebec
Study officials:
affiliation: CHUM-Centre Hospitalier de ''Universite de Montreal, Montreal, QC Canada
name: Arielle Elkrief
role: STUDY_CHAIR
affiliation: London Regional Cancer Program, London, ON Canada
name: John Lenehan
role: STUDY_CHAIR
References: